Show pagesourceBacklinksCite current pageExport to PDFBack to top Share via Share via... Twitter LinkedIn Facebook Pinterest Telegram WhatsApp Yammer Reddit TeamsRecent ChangesSend via e-MailPrintPermalink × HER2-positive brain metastases Reply to Letter to the Editor: 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by Y. Liu & C. ZhangEffects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic reviewStereotactic radiosurgery for HER2-positive breast cancer brain metastases: prognostic factors and the evolving role of anti-HER2 therapiesQuantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRIHER2-Positive Breast Cancer-Current Treatment Management and New Therapeutic Methods for Brain MetastasisAdvances in Targeted Therapy for Brain Metastases in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Focus on ADCs and TKIsLetter to the editor 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by F. Andre et alEfficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy Brain metastases (BM) are diagnosed in up to 40% of HER2-positive breast cancer patients. Treatment HER2-positive brain metastases treatment. her2-positive_brain_metastases.txt Last modified: 2025/03/11 22:33by 127.0.0.1